Pharma Launch Secrets podcast

First-in-Class VS Me-Too Launch Differences and the Role of Content, Hyperpersonalization, and Technology with Frank Dolan, Founder and CEO of ARSENAL

Manda indietro di 15 secondi
Manda avanti di 15 secondi
First-in-class medications are often referred to as innovative treatment alternatives. But innovation might scare and push away some HCPs and patients. In this episode of Pharma Launch Secrets, Bozidar is joined by Frank Dolan, Founder, and CEO of ARSENAL

Altri episodi di "Pharma Launch Secrets"